Page last updated: 2024-08-18

pyrazolanthrone and Hepatic Failure

pyrazolanthrone has been researched along with Hepatic Failure in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aoyagi, Y; Honda, Y; Ichida, T; Matsuda, Y; Suzuki, K; Takamura, M; Tamura, Y; Yamagiwa, S	1

Other Studies

1 other study(ies) available for pyrazolanthrone and Hepatic Failure

Article	Year
An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins. Life sciences, 2007, Mar-13, Volume: 80, Issue:14 Topics: Alanine Transaminase; Animals; Anthracenes; Apoptosis; Aspartate Aminotransferases; bcl-Associated Death Protein; BH3 Interacting Domain Death Agonist Protein; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Enzyme Inhibitors; Galactosamine; Hepatocytes; Injections, Intraperitoneal; Injections, Subcutaneous; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Liver Failure; Longevity; Male; Mice; Mice, Inbred BALB C; Peptide Fragments; Proto-Oncogene Proteins	2007

Article

Year

An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins.

Life sciences, 2007, Mar-13, Volume: 80, Issue:14

Topics: Alanine Transaminase; Animals; Anthracenes; Apoptosis; Aspartate Aminotransferases; bcl-Associated Death Protein; BH3 Interacting Domain Death Agonist Protein; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Enzyme Inhibitors; Galactosamine; Hepatocytes; Injections, Intraperitoneal; Injections, Subcutaneous; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Liver Failure; Longevity; Male; Mice; Mice, Inbred BALB C; Peptide Fragments; Proto-Oncogene Proteins

2007